Project Grant R01CA308352
Award Date 4/7/26
Completion Date 3/31/31
Dollars Obligated $586K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...
- Federal Grant Award Summary The National Cancer Institute awarded University of California, Irvine a $648,626 Project Grant on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI). The research, which runs through March 31, 2031, addresses a critical gap in cancer immunotherapy by examining why PD-1 (programmed death receptor 1) blockade and dual checkpoint inhibitor...
- Federal Grant Award Summary Western University of Health Sciences received a $429,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2028. The award funds the development and optimization of dual chimeric antigen receptor natural killer (CAR-NK) cells engineered to specifically target acute myeloid leukemia (AML) cells with human leukocyte antigen (HLA)-DR loss. The research...
- Federal Grant Award Summary The University of California, Irvine received a $138,489 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded on September 20, 2025, with a completion date of September 19, 2027. The award supports research and development of a methyl arginine targeting chimera (MARTAc) for the lysosomal degradation of intracellular proteins. This project addresses critical limitations of current proteolysis-targeting...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The research project investigates dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining BCL-2 (B-cell lymphoma-2) inhibition with CD123-directed natural killer (NK) cell engager immunotherapies. The research...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $650,597 to the University of California, San Diego, effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). The research project investigates the role of B-cells in generating durable complete responses to checkpoint blockade immunotherapy in head and neck squamous cell carcinoma patients. The study addresses the observation that while response rates...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- The University of California, Irvine (UCI) was awarded a $2,186,372 Project Grant under the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396). The 5-year grant, which began on April 1, 2025, will support a research program focused on understanding the fundamental biological mechanisms of cancer initiation and progression. The program includes three interdisciplinary research projects that will leverage mouse models to investigate the role of stochastic,...